Premier Event Showcases Innovative Growth Companies and Connects Them with Leading Institutional Investors
MINNEAPOLIS, MN - October 27, 2025 (NEWMEDIAWIRE) - PetVivo Holdings, Inc. (OTCQX: PETV; OTCID PETVW), a leading provider of biomedical therapeutics for equines and companion animals, is proud to announce that it will present at the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025, at the Marriott Marquis Hotel in New York City.
Participation by PetVivo Holdings, Inc. underscores the conference’s mission to spotlight innovative companies and emerging market leaders positioned for long-term growth.
"We are excited to share our company’s story with such a distinguished audience of investors and peers," said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "The Spartan Capital Conference offers an unparalleled platform to highlight our progress, connect with new investors, and strengthen relationships within the capital markets community."
Mr. Lai intends to provide an overview of PetVivo Holdings, Inc. as well as discuss its flagship products, SPRYNG(TM) with OsteoCushion(TM) Technology and PrecisePRP(R). SPRYNG with OsteoCushion Technology, is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
PrecisePRP is a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians. PrecisePRP is a leucoreduced, allogeneic, pooled, freeze-dried PRP intended to provide a species-specific source of concentrated platelets in plasma for intra-articular administration in dogs and horses. Unlike any PRP mechanical kits currently on the market, PrecisePRP™ does not require a blood draw or centrifugation making it a truly off-the-shelf product that is easy and convenient. Perhaps more important is the uniformity and consistency that PrecisePRP® guarantees. Each vial of PrecisePRP(R) contains a consistent dose of 4 billion platelets per vial at a concentration of 500,000 platelets per microliter and is leucoreduced with less than 1500 white blood cells per microliter.
"We are delighted to feature PetVivo Holdings, Inc. at our second annual investor conference," said John D. Lowry, Founder and Chief Executive Officer of Spartan Capital Securities, LLC. "Spartan Capital has built its reputation on helping growth companies access the right investors and resources, and this conference is a powerful extension of that mission - bringing together high-quality issuers and serious capital providers under one roof."
Organized in partnership with B2i Digital, the conference will showcase more than 60 carefully selected companies across technology, healthcare, consumer, mining, precious metals, and other high-growth sectors. Over 500 institutional and high-net-worth investors are expected to attend.
“In collaboration with Spartan Capital’s banking team, we invited PetVivo Holdings, Inc. to share their perspective with the investors in attendance,” said David Shapiro, CEO of B2i Digital. “Their participation is part of our broader commitment to connecting investors with a diverse range of growth companies, supporting B2i Digital’s core mission - combining the broad reach of digital marketing with the powerful impact of face-to-face investor engagement.”
The event will feature main-stage presentations, expert panels, curated one-on-one meetings, and extensive networking sessions, creating meaningful opportunities for dialogue between growth companies and the investment community.
For more information about the conference and registration details, please visit Spartan Capital Investor Conference 2025 Registration.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQX: PETV; OTCID: PETVW), in cooperation with its wholly-owned subsidiary PetVivo Animal Health, Inc., is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve patents and six trade secrets protect the Company's biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG(R) with OsteoCushion® technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP®, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
About Spartan Capital Securities, LLC
Spartan Capital Securities, LLC (Member FINRA/SIPC/MSRB) is a premier full-service financial firm offering expert investment advice to high-net-worth individuals and institutional clients. Known for its extensive market knowledge, strategic risk management, and personalized service, Spartan Capital and CEO John Lowry exemplify integrity and professionalism in the financial services industry.
Spartan Capital Securities Contact:
Kim Monchik
45 Broadway, 19th Floor
New York, NY 10006
https://spartancapital.com
212.293.0123
Info@spartancapital.com
https://www.facebook.com/spartancapital/
https://www.linkedin.com/company/spartan-capital-securities-llc/
https://x.com/SpartanCapSec
About B2i Digital, Inc.
B2i Digital, Inc. partners with leading investor conferences, public companies, and capital markets advisors through its signature programs: Featured Conference, Featured Company, and Featured Expert. Utilizing advanced digital marketing strategies, a network of 1.4 million investors, and highly targeted introductions, B2i Digital helps connect key stakeholders across the financial markets. The company was founded in 2021 by David Shapiro, who previously served as both an Investment Banker at Maxim Group and its Chief Marketing Officer.
B2i Digital Contact:
David Shapiro
Chief Executive Officer
B2i Digital, Inc.
https://b2idigital.com
212.579.4844 Office
david@b2idigital.com
https://www.linkedin.com/in/davidshapironyc
https://www.linkedin.com/company/b2i-digital
https://x.com/b2idigital
https://www.facebook.com/b2idigital
https://www.instagram.com/b2i_digital
https://www.youtube.com/@b2idigital
https://www.pinterest.com/b2idigital/
https://www.tiktok.com/@b2idigital
https://www.threads.net/@b2i_digital
https://stocktwits.com/B2iDigital
https://www.reddit.com/user/b2idigital/
https://bsky.app/profile/b2idigital.bsky.social
Disclosure Information
PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company’s Investor Relations website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations and webcasts.
Forward-Looking Commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
View the original release on www.newmediawire.com
